News und Analysen

Viking Therapeutics (NASDAQ: VKTX) is aiming to join one of the biggest growth industries of the times: the weight loss drug market. People hoping to lose weight have rushed to get in on GLP-1

Smart investors already know that the artificial intelligence (AI) revolution has served as a generational bellwether for semiconductor stocks. Over the last few years, capital expenditure budgets

Michael K Liu, EVP - Operations at Knight-Swift (NYSE:KNX), disposed of 1,243 directly held shares in an open-market sale on Feb. 4, 2026, fully exiting his direct equity position according to a SEC

Despite its fourth-quarter results being pretty solid, the share price of pharmaceutical giant AbbVie (NYSE: ABBV) fell after the company released earnings last week. The market reacted poorly to

Spending on artificial intelligence (AI) infrastructure is surging. Five companies have committed to spending $700 billion on AI infrastructure this year by themselves, while famed portfolio manager

The pharmaceutical industry can be a tricky investment.

Remember Pfizer (NYSE: PFE) back in 2020? Its stock price shot from around $33 in February 2020 to nearly $60 by December due to its rapid

On February 13, 2026, Affinity Asset Advisors disclosed a new position in Praxis Precision Medicines (NASDAQ:PRAX), acquiring 185,000 shares in an estimated $54.53 million trade.

According to a SEC

Healthcare industry stocks are traditionally good hedges against technology and other growth stocks, because they tend to perform well when the larger stock markets do not.

But it depends on which

By all accounts its stock should be in the red today. CRISPR Therapeutics (NASDAQ: CRSP) only reported $864,000 in fourth-quarter revenue after Thursday's closing bell, leading to a loss of $1.37

Pharmaceutical giant Eli Lilly (NYSE: LLY) has been the winner in the massive GLP-1 drug category, the class of medications that have proven extremely effective in lowering blood sugar levels and

Pfizer (NYSE: PFE) has a well-above-market dividend yield of 6.3%. Despite a payout ratio that is over 100%, the drugmaker states that it plans to maintain the dividend. But the real catalyst for a

You may not immediately recognize the name Abbott Laboratories (NYSE: ABT), but you've probably come into close contact with one of the company's many products -- from a coronavirus test to Ensure

Thirteen years ago, AbbVie (NYSE: ABBV) didn't exist -- at least not as a stand-alone company. It was an important part of Abbott Labs (NYSE: ABT) before being spun off as a separate entity. Today

Nvidia (NASDAQ: NVDA) has been the unquestioned leader in GPU chips for artificial intelligence (AI) data centers since the start of the AI boom in early 2023.

Perhaps the most impressive feat is

Shares in Advanced Energy Industries (NASDAQ: AEIS) powered higher by more than 16% as of 12:45 a.m. today. The move comes after a well-received fourth-quarter earnings report that saw the company

Pfizer (NYSE: PFE) recently experienced yet another setback. The drugmaker has been posting disappointing financial results for several years, and its latest quarterly update sent its stock price

Solstice Advanced Materials (NASDAQ: SOLS) stock, the Honeywell (NASDAQ: HON) advanced materials and specialty chemicals division that spun off in October 2025, soared 15.2% through 12:35 a.m. ET

There are almost always some companies doing well, even when competitors in the same industry are sinking. Right now, investor enthusiasm has GLP-1 weight loss drug leader Eli Lilly (NYSE: LLY)

When most people think about GLP-1 drugs, they think of the blockbuster products sold by pharma giants Eli Lilly and Novo Nordisk. Lilly makes Mounjaro and Zepbound, while Novo makes Ozempic and

Eli Lilly (NYSE: LLY) has crushed the market over the past decade, largely thanks to breakthroughs within its core therapeutic area. Some might think it's too late to invest in the stock. Eli Lilly

Vertex Pharmaceuticals (NASDAQ: VRTX) is a great example of a biotech success story. The company has developed strength in a specialty area and, thanks to that, has delivered a track record of

Vertex Pharmaceuticals (NASDAQ: VRTX) has underperformed the market over the past year, rising less than 2%. The biotech, known for its cystic fibrosis (CF) treatments, is scheduled to report

Vertex Pharmaceuticals (NASDAQ: VRTX) experienced several setbacks last year, sometimes following quarterly updates that weren't as strong as the market expected, or during which it also reported